The strong Phase 1 data de-risk zoldonrasib’s development and support potential accelerated approval pathways; traders should monitor for upcoming Phase 2 trial initiation or combination study readouts as next catalysts.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $146.23entry
- T+1 · 7mo ago +1.83%α +2.48% · $148.90
- T+5 · 7mo ago −9.96%α −10.87% · $131.67
- T+20 · 6mo ago −1.27%α −5.47% · $144.37
- T+60 · 4mo ago +26.13%α +19.35% · $184.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced updated Phase 1 data for zoldonrasib in KRAS G12D non-small cell lung cancer, showing a 52% confirmed objective response rate and 11.1-month median progression-free survival, supporting its potential as a first-in-class targeted therapy for a high-unmet-need population.
Key Facts
- Zoldonrasib showed a 52% confirmed objective response rate (ORR) in 27 evaluable KRAS G12D NSCLC patients previously treated with immunotherapy and chemotherapy.
- Median progression-free survival (PFS) was 11.1 months, with a 12-month PFS rate of 48%.
- The safety profile was manageable, with Grade 3 treatment-related adverse events in 13% of patients and no Grade 4 or 5 events.
- Data were presented at AACR 2026 and represent a key milestone in validating zoldonrasib’s clinical potential.
Financial Impact
High-value potential in a niche but significant oncology market; ~2,500 new KRAS G12D NSCLC patients annually in the U.S. and ~61,000 across all cancers.
Risk Factors
- Phase 1 data may not translate to later-stage success.
- Competitive landscape could shift with other RAS inhibitors in development.
- Regulatory path remains uncertain without Phase 3 plans yet disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276666 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers